Key Laboratory of Carcinogenesis and Translational Research, Department of Pathology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, China.
World J Gastroenterol. 2012 Jan 28;18(4):368-74. doi: 10.3748/wjg.v18.i4.368.
To investigate the association between single nucleotide polymorphisms (SNPs) in intercellular adhesion molecule-1 (ICAM-1) and the risk, biological behavior and prognosis of gastric cancer (GC) in Chinese population.
The study group consisted of 332 GC patients and 380 healthy controls. Genotyping was performed using polymerase chain reaction and the results were confirmed by sequencing. The association of ICAM-1 K469E polymorphisms and the risk of GC were studied, and the correlation of ICAM-1 K469E polymorphisms with the clinicopathological parameters and prognosis of the patients with complete clinical and follow-up data was analyzed.
Carriers of AA genotype had a significantly increased risk of GC compared with carriers of AG and GG genotypes [odds ratios: 1.36; 95% confidence interval (CI): 1.01-1.84; P = 0.041]. GC patients with AA genotype were more prone to distant metastasis than those carrying AG and GG genotypes (18.9% vs 7.0%, respectively; P = 0.002). In addition, patients at stage IV had significantly more carriers of AA genotype than those of AG and GG genotype (27.4% vs 16.9%, respectively; P = 0.046). Follow-up study showed that the overall cumulative survival rate was 23.7% in AA genotype group and 42.9% in AG and GG genotypes group. In univariate analysis, AA genotype was correlated with the overall cumulative survival (P = 0.034). But in multivariate analysis, ICAM-1 polymorphism was not an independent prognostic factor for the overall survival (relative risk, 1.145; 95% CI: 0.851-1.540; P = 0.370).
Polymorphisms of ICAM-1 K469E can be a useful biomarker for identifying individuals with higher risk of GC, predicting disease progression, and guiding individualized treatment.
研究细胞间黏附分子-1（ICAM-1）单核苷酸多态性（SNP）与中国人群胃癌（GC）的风险、生物学行为和预后的关系。
研究组包括 332 例 GC 患者和 380 例健康对照者。采用聚合酶链反应进行基因分型，并用测序结果进行确认。研究了 ICAM-1 K469E 多态性与 GC 风险的关系，并分析了 ICAM-1 K469E 多态性与具有完整临床和随访数据的患者临床病理参数和预后的相关性。
与 AG 和 GG 基因型携带者相比，AA 基因型携带者发生 GC 的风险显著增加[比值比：1.36；95%置信区间（CI）：1.01-1.84；P = 0.041]。携带 AA 基因型的 GC 患者发生远处转移的倾向明显高于携带 AG 和 GG 基因型的患者（18.9%比 7.0%；P = 0.002）。此外，IV 期患者中 AA 基因型携带者明显多于 AG 和 GG 基因型携带者（27.4%比 16.9%；P = 0.046）。随访研究显示，AA 基因型组的总累积生存率为 23.7%，AG 和 GG 基因型组为 42.9%。单因素分析显示，AA 基因型与总累积生存率相关（P = 0.034）。但多因素分析显示，ICAM-1 多态性不是总生存的独立预后因素（相对风险，1.145；95%CI：0.851-1.540；P = 0.370）。
ICAM-1 K469E 多态性可以作为识别 GC 风险较高个体的有用生物标志物，预测疾病进展，并指导个体化治疗。
